News
Hims & Hers, Novo Nordisk Team Up to Offer Weight-Loss Treatment Drugs
Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity. Consumers will now be able to access NovoCare Pharmacy through Him & Hers' platform as well as clinical support, nutrition guidance and a membership, the companies said in a statement Tuesday.
Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...
U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral ...
But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...
Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...
Eli Lilly reports positive late-stage data for its weight-loss pill. BMO analyst says Lilly's update will weigh on shares of ...
Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback